ORCHARD THERAPEUTICS PLC-ADR (ORTX) Stock Price, Quote, News and Overview
NASDAQ:ORTX - Nasdaq - US68570P2002 - ADR - Currency: USD
ORTX Quote, Performance and Key Statistics
NASDAQ:ORTX (1/23/2024, 8:00:02 PM)
16.7
+0.05 (+0.3%)
The current stock price of ORTX is 16.7 USD. In the past month the price increased by 1.58%. In the past year, price increased by 195%.
ORTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ORTX
Company Profile
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The firm is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Company Info
ORCHARD THERAPEUTICS PLC-ADR
245 Hammersmith Road, 3Rd Floor
London EC4N 6EU GB
CEO: Bobby Gaspar
Employees: 166
Company Website: https://www.orchard-tx.com/
Phone: 114402033846700
ORCHARD THERAPEUTICS PLC-ADR / ORTX FAQ
What is the stock price of ORCHARD THERAPEUTICS PLC-ADR today?
The current stock price of ORTX is 16.7 USD. The price increased by 0.3% in the last trading session.
What is the ticker symbol for ORCHARD THERAPEUTICS PLC-ADR stock?
The exchange symbol of ORCHARD THERAPEUTICS PLC-ADR is ORTX and it is listed on the Nasdaq exchange.
On which exchange is ORTX stock listed?
ORTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORCHARD THERAPEUTICS PLC-ADR stock?
7 analysts have analysed ORTX and the average price target is 16.32 USD. This implies a price decrease of -2.28% is expected in the next year compared to the current price of 16.7. Check the ORCHARD THERAPEUTICS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORCHARD THERAPEUTICS PLC-ADR worth?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) has a market capitalization of 380.11M USD. This makes ORTX a Small Cap stock.
How many employees does ORCHARD THERAPEUTICS PLC-ADR have?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) currently has 166 employees.
What are the support and resistance levels for ORCHARD THERAPEUTICS PLC-ADR (ORTX) stock?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) has a support level at 16.52 and a resistance level at 16.71. Check the full technical report for a detailed analysis of ORTX support and resistance levels.
Is ORCHARD THERAPEUTICS PLC-ADR (ORTX) expected to grow?
The Revenue of ORCHARD THERAPEUTICS PLC-ADR (ORTX) is expected to grow by 24% in the next year. Check the estimates tab for more information on the ORTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ORCHARD THERAPEUTICS PLC-ADR (ORTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORTX, evaluating the profitability, health, valuation and growth aspects
- ORCHARD THERAPEUTICS PLC-ADR (ORTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORCHARD THERAPEUTICS PLC-ADR (ORTX) Sales and EPS estimates to see what analysts future expectations are.
- ORCHARD THERAPEUTICS PLC-ADR (ORTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORCHARD THERAPEUTICS PLC-ADR (ORTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORCHARD THERAPEUTICS PLC-ADR (ORTX) Stock Chart to make your own analysis
- ORCHARD THERAPEUTICS PLC-ADR (ORTX) Latest news and press-releases to stay up to date.
Does ORCHARD THERAPEUTICS PLC-ADR (ORTX) stock pay dividends?
ORTX does not pay a dividend.
When does ORCHARD THERAPEUTICS PLC-ADR (ORTX) report earnings?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) will report earnings on 2024-03-05, after the market close.
What is the Price/Earnings (PE) ratio of ORCHARD THERAPEUTICS PLC-ADR (ORTX)?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4).
ORTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ORTX. When comparing the yearly performance of all stocks, ORTX is one of the better performing stocks in the market, outperforming 98.06% of all stocks.
ORTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORTX. ORTX has a bad profitability rating. Also its financial health evaluation is rather negative.
ORTX Financial Highlights
Over the last trailing twelve months ORTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS increased by 71.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| Debt/Equity | 0.2 |
ORTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to ORTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 74.37% and a revenue growth 24% for ORTX